Cost-Effectiveness of Intravenous Immunoglobulin Use in Neurology
Author Information
Author(s): Jonathan O’Riordan, Robert J. Swingler, Naveed M. Malek
Primary Institution: Ninewells Hospital, NHS Tayside
Hypothesis
The study aims to identify the indications for prescription of intravenous immunoglobulin (IVIg) in neurology and assess the cost-effectiveness of this therapy.
Conclusion
Implementing cost-saving measures could potentially save £330,000 annually from the health budget at Ninewells Hospital.
Supporting Evidence
- The cost of IVIg therapy has increased by almost 300% from 2004-2005 to 2008-2009.
- The annual budget for IVIg at Ninewells Hospital is close to £1.5 million.
- Patients reported subjective and objective improvements after IVIg therapy.
Takeaway
This study looks at how much money is spent on a special treatment called IVIg for patients in a hospital and suggests ways to save money while still helping people.
Methodology
The study audited two time periods over 12 months each in 2004–2005 and 2008–2009 to analyze IVIg utilization and costs.
Potential Biases
Potential bias in prescription practices due to varying interpretations of clinical trial data.
Limitations
The study may not account for all variables affecting the cost and effectiveness of IVIg therapy.
Participant Demographics
Patients included a mix of ages from 26 to 93 years, with both male and female participants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website